3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Breast Neoplasms
8
Prostatic Neoplasms
7
Colorectal Neoplasms
4
Colorectal Neoplasms, Hereditary Nonpolyposis
3
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplastic Syndromes, Hereditary
2
Colonic Neoplasms
2
Carcinoma, Intraductal, Noninfiltrating
2
Tuberous Sclerosis
1
Thyroid Neoplasms
1
Sarcoma
1
Pyloric Stenosis, Hypertrophic
1
Primary Ovarian Insufficiency
1
Polycystic Ovary Syndrome
1
Pheochromocytoma
1
Pediatric Solid Tumor
1
Paraganglioma
1
Pancreatic Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphangioleiomyomatosis
1
Lipodystrophy, Familial Partial
1
Kidney Neoplasms
1
Histiocytosis, Non-Langerhans-Cell
1
Interventions
pembrolizumab
90
Blood Specimen Collection
41
Cyclophosphamide
37
Bevacizumab
36
Nivolumab
35
Standard of Care
32
Carboplatin
31
Surveys and Questionnaires
29
Paclitaxel
27
atezolizumab
25
Exercise
25
Pemetrexed
24
Gemcitabine
24
Cisplatin
23
Fluorouracil
22
Radiotherapy
20
Leucovorin
20
Dexamethasone
20
Docetaxel
19
Oxaliplatin
18
Rituximab
16
Irinotecan
16
Cetuximab
16
dostarlimab
15
Drug Therapy
15
Doxorubicin
15
Ipilimumab
14
Biopsy
14
130-nm albumin-bound paclitaxel
14
fludarabine
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Genetic Testing
×
1 year
×
Clear all
NCT06008392
2026-04-07
INTERCEPTioN
Mayo Clinic
Recruiting
500 enrolled